![Alison Milhous](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 4 219 $ in data 30/09/2026
Alison Tjosvold Milhous is currently an Independent Director at VivoSim Labs, Inc. since 2020 and Vice President-Accounting at Erasca, Inc. since 2021.
Formerly, Ms. Milhous was an Audit Partner at Grant Thornton LLP from 2015 to 2019.
Education includes undergraduate studies at California Polytechnic State University (San Luis Obispo).
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
VIVOSIM LABS INC 0,77% | 13/08/2026 | 19.899 ( 0,77% ) | 4 219 $ | 30/09/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| VIVOSIM LABS, INC. | Direttore/Membro del Consiglio | 15/09/2020 |
| ERASCA, INC. | Comptroller/Controller/Auditor | 01/11/2021 |
| Società | Posizione | Fine |
|---|---|---|
Grant Thornton LLP
 Grant Thornton LLP Miscellaneous Commercial ServicesCommercial Services Provides accounting, assurance, tax and advisory services | Corporate Officer/Principal | 01/09/2019 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
VivoSim Labs, Inc.
 VivoSim Labs, Inc. BiotechnologyHealth Technology Engages in developing and commercializing functional human tissues | Health Technology |
Grant Thornton LLP
Grant Thornton LLP Miscellaneous Commercial ServicesCommercial Services Provides accounting, assurance, tax and advisory services | Commercial Services |
California Polytechnic State University (San Luis Obispo)
 California Polytechnic State University (San Luis Obispo) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Erasca, Inc.
 Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
